TABLE 4.

Species distribution and susceptibility to fluconazole among Candida isolates obtained in two randomized trials of fluconazole in the treatment of candidemia

Species	Clinical study, time perioda
	Rex (83), 1989-1993b				Ostrosky-Zeichner (54), 1995-1999c
	n	MIC50	MIC90	%R	n	MIC50	MIC90	%R
C. albicans	129	0.25	1	<1	733	0.25	2	5
C. glabrata	31	16	32	10	458	8	32	8
C. parapsilosis	23	1	4	0	391	1	2	2
C. tropicalis	40	1d	>64d	25d	307	0.5	16	8
C. krusei	6	32	ND	NA	50	32	>64	34
C. lusitaniae	3	0.5	ND	NA	20	0.5	2	0

^aMIC₅₀ and MIC₉₀, MIC encompassing 50% and 90% of isolates tested, respectively; %R, percent resistant at MIC of ≥64 μg/ml; ND, not done (<10 isolates); NA, not available.

^bIsolates tested by broth macrodilution (NCCLS, M27-A) (48).

^cIsolates tested by CLSI M27-A2 broth microdilution (50).

^dTrailing artifact. When retested using CLSI broth microdilution and reading MIC at 24 h of incubation, MIC_50/90 values were 0.25 and 1 μg/ml, respectively (83).